AnaptysBio, Inc. (NASDAQ:ANAB) Given Average Rating of “Moderate Buy” by Analysts

Chronological Source Flow
Back

AI Fusion Summary

AnaptysBio (ANAB) has a consensus “Moderate Buy” rating from 11 analysts—9 buy, 1 sell, 1 hold—with an average 1‑year price target of $80.10. Wedbush raised its target to $75, while HC Wainwright set $66, reflecting optimism about the company’s pipeline and clinical milestones.
#AnaptysBio #Moderate Buy #Analyst Ratings #Price Target #Pipeline #Clinical Milestones #Wedbush #HC Wainwright
01/04 10:41 defenseworld.net
3 Πηγές

AnaptysBio, Inc. (NASDAQ:ANAB) Given Average Rating of “Moderate Buy” by Analysts

AnaptysBioModerate BuyAnalyst RatingsPrice TargetPipelineClinical Milestones
01/04 11:43 defenseworld.net

Plexus Corp. (NASDAQ:PLXS) Given Consensus Rating of “Moderate Buy” by Analysts

CONSENSUS RATING ARTICLESCOMPANIESPOLITICS
01/04 11:43 defenseworld.net

First Financial Bancorp. (NASDAQ:FFBC) Given Average Rating of “Moderate Buy” by Analysts

CONSENSUS RATING ARTICLESECONOMYCOMPANIESPOLITICS
Comments
Loading...
0